Intellectual Asset Management Recognizes Foley Attorneys in 2020 Patent 1000 Guide
01 May 2020
Intellectual Asset Management (IAM) has recognized 16 Foley attorneys in the 9th edition of its Patent 1000 – The World’s Leading Patent Professionals guide. Additionally, the firm was recognized for offices and practices, including the District of Columbia (prosecution), Boston (prosecution and litigation) Detroit, Milwaukee and Tokyo (litigation).
The Foley attorneys recognized include:
- Scott Anderson, prosecution
- Courtenay Brinckerhoff, prosecution
- Jeffrey Costakos, litigation
- Etsuo Doi, transactions
- Jeanne Gills, litigation
- Jeffrey Gundersen, prosecution
- John Lanza, prosecution
- Matthew Lowrie, litigation
- Stephen Maebius, post-grant proceedings, prosecution, transactions
- Christopher McKenna, prosecution
- George Quillin, post-grant proceedings, prosecution
- Michele Simkin, prosecution
- Gary Solomon, prosecution
- Eric Sophir, prosecution
-
Marcus Sprow, prosecution
- Joseph Ziebert, prosecution
The Patent 1000 – The World’s Leading Patent Professionals guide is compiled by a team of researchers from IAM magazine based on more than 1,800 interviews with private practice and in-house professionals regarding the full range of patent services.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”